专业监测看板

Trizivir

药物 / 成分：abacavir (as sulfate);lamivudine;zidovudine

(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

药物 / 成分：Recombinant human alkaline phosphatase、Placebo

登记的停止原因（原文）：The Data Monitoring Committee (DMC) concluded that the pre-specified futility threshold was met and that there was no safety concern.

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

药物 / 成分：Neoantigen specific TCR-T cell drug product、Aldesleukin (IL-2)

登记的停止原因（原文）：Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell manufacturing. The study was not stopped for safety reasons.

Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

药物 / 成分：KP104

登记的停止原因（原文）：Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

药物 / 成分：Montanide (Registered Trademark) ISA-51 VG Adjuvant、H1299 Cell Lysates、N-803、Ventana PD-L1 (SP263 or SP142) assay

登记的停止原因（原文）：Revisions to eligibility/design being made prior to enrollment of first participants.

High-Dose Ambroxol in GBA1-Related Parkinson

药物 / 成分：Ambroxol Hydrochloride

登记的停止原因（原文）：Sponsor's decision

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

药物 / 成分：azacytidine、carboplatin、paclitaxel、durvalumab

登记的停止原因（原文）：Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

药物 / 成分：Mirdametinib、Sirolimus

登记的停止原因（原文）：Administrative hold pending non-safety related changes to the study design.

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

药物 / 成分：OPB-101

登记的停止原因（原文）：Business decision

Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

药物 / 成分：Zanzalintinib

登记的停止原因（原文）：Funder withdrew

A Repeat Dose Study of the Dexmedetomidine Transdermal System in Healthy Subjects

药物 / 成分：Dexmedetomidine Transdermal System (DMTS)

登记的停止原因（原文）：Sponsor decision, after observation of adverse events

Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults

药物 / 成分：Oxfendazole、Albendazole

登记的停止原因（原文）：Study cancelled prior to initiation as the Oxfendazole Development Group is collaborating on a similar study being conducted by AB Prisma, NCT4713787

Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis

药物 / 成分：Colchicine

登记的停止原因（原文）：Sponser decision

Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

药物 / 成分：Pembrolizumab、Hypofractionated radiation therapy

登记的停止原因（原文）：protocol amendment

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

药物 / 成分：Emicizumab、FEIBA、rFVIIa

登记的停止原因（原文）：The study was withdrawn because the pharmaceutical sponsor withdrew support for the study. No participants were enrolled before termination.

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

药物 / 成分：JDQ443、docetaxel

登记的停止原因（原文）：Business reasons and not based on any safety concerns.

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

药物 / 成分：Chemotherapy、Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)

登记的停止原因（原文）：Halted prematurely

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2

药物 / 成分：Varenicline

登记的停止原因（原文）：recruitment challenges

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

药物 / 成分：Budigalimab、Placebo for Budigalimab、ABBV-382、Placebo for ABBV-382

登记的停止原因（原文）：Company Decision

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

药物 / 成分：delandistrogene moxeparvovec、imlifidase

登记的停止原因（原文）：Study is being terminated due to a business decision.